Pharma BD Deal Intelligence
Roche's $759M bet on Tusk Therapeutics' anti-CD25 Treg-depleting antibody RG6292 ended in bust: both Phase 1 studies were terminated for insufficient efficacy, and published 2025 results confirmed the program had no path forward.
Lead asset flunked Phase 1 efficacy bar and the program appears quietly discontinued — a ~$0.8B bolt-on that didn't pay off
Full analysis, sources & comparables →Vantage's Jonathan Gardner noted Roche became the first big pharma to complete a Treg-focused oncology deal, capitalizing on a hot immuno-oncology theme to…
The Tusk acquisition gives Roche a differentiated Treg-depleting antibody that preserves IL-2 signaling on effector T cells, a mechanistic advantage over…
NCT04642365 (BP42595): Phase 1 study of RO7296682 (RG6292) + atezolizumab in advanced solid tumors. Overall status TERMINATED 2024-01-04; sponsor cited…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Roche acquired UK-Belgian biotech Tusk Therapeutics in September 2018 for EUR 70M (~$81M) upfront plus up to EUR 585M (~$678M) in development and commercial milestones (total up to EUR 655M / ~$759M). The deal added Tusk's preclinical anti-CD25 antibody designed to deplete regulatory T cells in tumors without blocking IL-2 signaling, the first major pharma Treg-targeting oncology buyout. Roche advanced the asset (RG6292 / RO7296682 / vopikitug) into two Phase 1 studies, but both were terminated: the monotherapy study (NCT04158583) completed in July 2022 and the atezolizumab-combination study (NCT04642365) was terminated in January 2024 citing a low likelihood of achieving the targeted efficacy. Phase 1 results published in 2025 (Cancer Research Communications) concluded that RG6292 alone or with atezolizumab showed insufficient clinical efficacy to warrant further exploration, ending the program. The acquisition closed as announced; the milestone-heavy contingent value was almost certainly never realized, though Roche does not disclose milestone payments.
Lead asset flunked Phase 1 efficacy bar and the program appears quietly discontinued — a ~$0.8B bolt-on that didn't pay off
Assessment window: 5yr post-close.
Regulatory T cells (Tregs) infiltrate the tumor microenvironment and suppress anti-tumor immune responses, driving resistance to checkpoint inhibitors. Selective depletion of CD25-high tumor Tregs without disrupting IL-2 signaling on effector T cells is a leading approach to enhance immuno-oncology combinations across solid tumors.
By 2018, Treg-targeting was a hot immuno-oncology theme, with multiple anti-CD25 and Treg-depleting programs racing to clinic. Direct competitors included ADC Therapeutics' camidanlumab tesirine (ADCT-301, anti-CD25 PBD ADC, Phase 1 NCT03621982), Pandion Therapeutics' Treg-targeted approaches, and academic programs from Cancer Research UK (which had partnered with Tusk on the Fc-optimized anti-CD25 concept — see https://www.sciencedirect.com/science/article/pii/S1074761317301231 ). First-generation anti-CD25 (basiliximab/daclizumab, used in transplant) blocked IL-2 binding and was suboptimal for tumor settings — Tusk's IL-2 sparing antibody (RG6292/RO7296682) was differentiated by preserving IL-2 signaling on effectors while selectively depleting Tregs via ADCC. BioPharma Dive characterized Roche as 'the first big pharma to complete a Treg deal focused on oncology,' establishing a leadership position alongside its Tecentriq (atezolizumab) PD-L1 franchise. The deal complemented Roche's existing IO portfolio rather than competing with it, providing a combinatorial play to overcome PD-(L)1 resistance.
Roche halted the monotherapy arm of the Tusk-derived anti-CD25 antibody to focus on the atezolizumab combination, expecting higher efficacy in combination.
Roche terminated the combination study citing recruitment challenges and a low likelihood of achieving targeted efficacy, effectively ending the Tusk asset's clinical program.
Peer-reviewed Phase 1 results (Cancer Research Communications) concluded RG6292 alone or with atezolizumab showed insufficient clinical efficacy to warrant further exploration. The asset underpinning the 2018 acquisition failed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Tusk Therapeutics (this deal) | 2018 | $759M | 27 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2018 deals · Roche Holding AG deals · Oncology deals